Kanker-actueel = Zometa zoledronic acid provides significantly less risk of breaking bones and better recovery (81%) of bone problems and provides significantly better overall survival in breast, prostate and lung cancer patients compared with botuitzaaiingen APD and pl

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

= Zometa zoledronic acid immediately after surgery in women with early breast cancer who Femara - Letrozole use provides better protection against bone loss and disease-free time than when Zometa is given only after significant bone loss or fracture occurs. Thus 3-year evaluation of Phase III trial of Z-FAST 602 breast cancer patients. Article updated October 1, 2009.

= Zometa zoledronic acid (a bisphosphonate) receives FDA approval for drug use in bone problems of cancer, including prostate cancer and multiple myeloma patients - Multiple Myeloma patients. Article posted February 2002

= Zometa zoledronic acid provides significantly less risk of breaking bones and better recovery (81%) of bone problems and provides significantly better overall survival in breast, prostate and lung cancer patients compared with botuitzaaiingen APD and placebo, according to three large Phase III trials. Article updated October 1, 2009

= Zometa zoledronic acid (a bisphosphonate) gives 4 mg dose. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler) Scroll for study reports, etc. Article Update February 22, 2010

= Zometa zoledronic acid (a bisphosphonate) Information: New study shows once again increase our value and effectiveness of Zometa = zoledronic acid compared with APD injections for bone problems of cancer patients

= Zometa zoledronic acid (a bisphosphonate) Information: Zometa provides significantly better results in randomized phase III study in patients with recurrent prostate cancer and as an addition to hormone treatments.

= Zometa zoledronic acid (a bisphosphonate) Information: FDA warns against excessive dose of Zometa for patients with kidney problems. This may not exceed 4 mg. by injection administered.

= Zometa zoledronic acid (a bisphosphonate) information: A survey of three double-blind randomized controlled trials shows that Zometa - zoledronic ACD far better results than APD = pamidronate on bone problems (eg fractures), longer time to first occur and significantly reduces botuitzaaiingen The bone pain in breast cancer, but also in bone metastatic prostate cancer, lung cancer, renal cell cancer and other solid tumors. Article posted October 24, 2005

= Zometa zoledronic acid (a bisphosphonate) shows work best and even cost-effective means to botversterkende against bone loss in solid tumors. Article posted June 30, 2008

= Zometa zoledronic acid (a bisphosphonate) prevents bone loss in women with early breast cancer undergoing chemotherapy, according to randomized placebo-controlled phase III study. Article posted August 23, 2008

Zoledronic acid 4 mg dose gives. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler)

Zoledronic acid - Zometa significantly prolongs life in patients with multiple myeloma (Multiple Myeloma).

Bisphosphonates often cause bone problems in the jaw - osteonecrosis - evidenced by two recent studies. Article posted February 25, 2011

Zometa - zoledronic acid significantly prevents recurrence in women with breast cancer after the menopause and gives significantly better results in survival, but not in younger women. Estrogen levels appears to play a decisive role. Thus, large phase III study. Article updated March 19, 2011

Bisphosphonates increase in femur fracture risk but this risk does not outweigh benefits of bisphosphonates, according to major Swedish research in breast cancer patients. Article posted May 5, 2011

Learn how Zometa - zoledronic acid can be prescribed and fully compensated and given home can get. Article updated June 8, 2011

Zometa - zoledronic acid in addition to tamoxifen or Armidex disease-free time and better overall survival in breast cancer patients with hormone sensitive breast cancer, shows large randomized phase III study. Article posted June 8, 2011

Zometa - zoledronic acid for breast cancer in algmeen shows no significant positive effect only for postmenopausal women with breast cancer, Zometa in addition to chemotherapy 25 percent longer disease-free and overall survival it. A very special result. Article posted September 27, 2011

= Zometa zoledronic acid provides significantly less risk of breaking bones and better recovery (81%) of bone problems and provides significantly better overall survival in breast, prostate and lung cancer patients compared with botuitzaaiingen APD and placebo, according to three large Phase III trials. Article updated October 1, 2009

October 1, 2009: By popular demand, two recent major studies into the effect of Zometa highlighted. Please ask your oncologist instead Zometa APD.

July 26, 2008: Source Reuters

Zometa - zoledronic acid significantly reduces fracture risk and significantly improves overall survival in both breast cancer patients (81% achieved normal range), prostate cancer patients (70% reached normal values), and lung cancer patients (81% reached normal values), with botuitzaaiingen compared APD (65% reached normal levels in breast cancer patients) and placebo (8% reached normal levels in prostate cancer and 17% reached normal values in lung cancer).

This emerges from a survey study of three large randomized and placebo-controlled Phase III studies with APD to that cancer patients. Is not it incredible that the Netherlands still oncologists who dare say that APD has the same effect as Zometa. And it is our opinion that is still unheard of in the Netherlands almost all cancer patients with botuitzaaiingen Zometa is withheld in favor of APD.

Zoledronic Acid Reduces Fracture Risk in Cancer Patients With Bone Metastases

NEW YORK (Reuters Health) July 1918 - The bisphosphonates zoledronic acid normalizes or maintainAspectRatio N-telopeptide of type 1 collagen (NTX) levels in cancer patients with bone metastases, a multicenter team reports in the July 1 issue of Cancer.

Normalization of NTX and Stabilization of bone structure with zoledronic acid not only Reduces fracture risk, it improves overall survival, According To the results of a retrospective analysis of three large Phase III studies of cancer patients with bone metastases.

The analysis was led by Dr. Or Allan Lipton Milton S. Hershey Medical Center at Pennsylvania State University and 578 patiënten Involved with bone metastases from breast cancer, 472 patients with hormone-refractory prostate cancer and 291 patients with non-small cell lung cancer and Other solid tumors.

Patients Were Given Either control or zoledronic acid therapy, Which was pamidronate and placebo in breast cancer patients for prostate or lung cancer patients. Treatment was Given for up to 24 months.

Urinary NTX Levels Were Measured at baseline and again 3 months later. A normal NTX level was defined as 64 nmol Ntx / mmol creatinine or lower.

Most Patients with normal baseline NTX levels at normal levels Maintained with zoledronic acid therapy. In contrast, most patiënten with elevated NTX levels at baseline had a Normalization of NTX levels.

Normalization occurred with zoledronic acid in 81% of breast cancer patients, in 70% of prostate cancer patients and in 81% of lung cancer patients with initially elevated NTX levels.

NTX levels normalized with pamidronate therapy in breast cancer patients or 65%, while 8% and 17% of the prostate and lung cancer patients, respectively, normalized on placebo.

"Normalized NTX correlated with improved overall survival versus persistently elevated NTX," Dr. Lipton and colleagues report. "More About, réductions rate from baseline NTX levels correlated with Regard less or benefits whethere Patients transitioned from elevated to normal levels."

Cancer 2008, 113:193-201.